Kailera Therapeutics (KLRA): Post-180-Day Review: Heavyweight Backers, Lightweight Returns
KLRA's 62.5% IPO opening premium has vanished, with shares 33% below issue. Phase 3 enrollment is complete, but investor patience and aftermarket...
20 Views
Kailera Therapeutics (KLRA): Strong Appetite Fuels Kailera IPO Surge, Opens with Ten Point Premium
​Kailera Therapeutics IPO prices at $16, surges 62.5% on debut with strong institutional demand and promising obesity pipeline for long-term growth.
249 Views
Kailera Therapeutics (KLRA): Bain Backed Obesity Biotech Garners Significant Interest
​Kailera Therapeutics IPO sees strong demand, with potential for pricing strength and long-term value creation driven by promising weight loss drug...
462 Views
Primer: Kailera Therapeutics (KLRA US) - Apr 2026
Kailera Therapeutics is a clinical-stage biopharmaceutical company poised to enter the highly competitive but rapidly growing obesity...
190 Views
IPO Rating: Kailera Therapeutics, Inc.
✅ IPO PROPHET RATING: 7.72/10 🏦 Deal Quality & Underwriters: 8.4/10 Kailera Therapeutics is on the roadshow, marketing approximately 33.3...
145 Views